CS2 & CS12: Upper limb function results

SPINRAZA® can alter disease progression in later-onset SMA1

  • With SPINRAZA®, upper limb function continued to improve in non-ambulatory Type II patients over 3 years1

Change in ULM score1

Scheme
Scheme
Banner
Banner

Lauren
age 20 years*
Later-onset (Type III) SMA
treated with SPINRAZA®

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.